SINGAPORE – South Korea and India are likely to remain the leading players in the biosimilars space in Asia and widen the lead they have on China, which remains a distant third. Read More

SHANGHAI – U.S.-China biotech CASI Pharmaceuticals Inc. initiated dosing in Chinese patients with ENMD-2076, a selective angiogenic kinase inhibitor, in a phase II study for triple-negative breast cancer (TNBC). That marks CASI's first foray with ENMD-2076 in China. Read More

HONG KONG – Lack of proper staffing is the main reason for the huge drug approval backlog at the CFDA, which topped 18,000 applications last year. Though the regulator has plans to reduce the backlog in three years, it is facing other issues beyond the staffing problem. Read More

SHANGHAI – China's Ebola vaccine, Ad5-EBOL, is setting a new standard for technological capability and speed having generated strong phase I immunogenicity and safety data in Chinese patients within just three months. Read More

HONG KONG – China has released a draft of its long-awaited first-ever regulations on stem cell studies, which provide guidance for an industry with huge scientific and commercial potential. Read More

TOKYO – A lack of a commercial mindset is holding back Japan's biotech industry as academics find it difficult to move ideas from paper to market. Read More

HONG KONG – In a landmark study, Singapore-based researchers have identified a novel kinase feedback loop controlling autophagy in common RAS-driven cancers and have shown that combining a kinase inhibitor with an agent that prevents autophagy may offer an effective new approach to treating such tumors. Read More

HONG KONG – Calling success in the first proof-of-concept trial for its cancer drug, fruquintinib, Hong Kong-based Hutchison Medipharma said the drug achieved primary efficacy endpoints. Phase III trials will now start for the colorectal indication of fruquintinib, even as development continues in two other indications. Read More